- 403: Characterizing the 12 Amb a 1-U Ragweed Allergy Immunotherapy Tablet Adverse Event Profile in Adults with Ragweed-Induced Allergic Rhinoconjunctivitis
- 405: Safety of Ragweed Allergy Immunotherapy Tablet: Results From Four Placebo-Controlled Trials
- 809: Ragweed Allergy Immunotherapy Tablet Reduces Use of Ocular Antihistamines in Patients With Ragweed Pollen–Induced Allergic Rhinoconjunctivitis
- 810: Effect of Allergy Immunotherapy Tablet in Patients with or without Local Application-Site Reactions
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov).